Clinical Trial Update: A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs [Phase 3]

View source ↗

Summary

A Phase III trial comparing 177Lu-DOTATATE injections to long-acting Oxytrexine in adults with neuroendocrine tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 177Lu-DOTATATE (Lutetium-177 dotatate)
• Long-acting Oxytrexine (oxytrexine)

Snippet

Sponsor: HTA Co., Ltd. | Conditions: NETS Ga68 Lu177 | Phase 3 | Status: RECRUITING